Hagop Kantarjian
Overview
Explore the profile of Hagop Kantarjian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
1138
Citations
46513
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kugler E, Kantarjian H, Jabbour E, Khaire N, Short N, Kadia T, et al.
Cancer
. 2025 Feb;
131(5):e35773.
PMID: 39980368
Background: The BCR::ABL1 tyrosine kinase inhibitors (TKIs) have significantly improved the outcomes of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the optimal duration of TKI therapy in...
2.
Kawedia J, Rausch C, Liu X, Qiao W, DiNardo C, Daver N, et al.
Am J Hematol
. 2025 Jan;
100(4):740-743.
PMID: 39873236
No abstract available.
3.
Senapati J, Kantarjian H, Habib D, Haddad F, Jain N, Short N, et al.
Leuk Lymphoma
. 2025 Jan;
1-12.
PMID: 39791458
Using immunotherapeutic agents like inotuzumab ozogamicin (InO), blinatumomab, or chimeric antigen receptor T (CAR T)-cell therapy in frontline adult B-cell acute lymphoblastic leukemia (B-ALL) therapy is promising. These agents are...
4.
Kantarjian H, Short N, Jain N, Haddad F, Kadia T, Yilmaz M, et al.
Am J Hematol
. 2025 Jan;
100(3):402-407.
PMID: 39757533
Adding inotuzumab ozogamicin (InO) to hyper-CVAD and blinatumomab may improve outcomes in newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL). Patients with newly diagnosed B-ALL received up to...
5.
Paul S, Jabbour E, Nichols E, Short N, Kantarjian H
Leuk Lymphoma
. 2024 Nov;
66(3):389-399.
PMID: 39611241
Blinatumomab, a CD19/CD3 bispecific T-cell engager; inotuzumab ozogamicin (INO), a CD22 antibody drug conjugate; and chimeric-antigen receptor (CAR) T-cell constructs are novel immune-therapeutic options for treatment of acute lymphoblastic leukemia...
6.
Haddad F, Sasaki K, Senapati J, Hu S, Dellasala S, Issa G, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
PMID: 39592322
Introduction: The discontinuation of third-generation BCR::ABL1 tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in chronic phase (CML-CP) is not well understood. We aim to evaluate treatment-free remission...
7.
Jabbour E, Oehler V, Koller P, Jamy O, Lomaia E, Hunter A, et al.
JAMA Oncol
. 2024 Nov;
11(1):28-35.
PMID: 39570620
Importance: Patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) resistant or intolerant to BCR-ABL1 tyrosine kinase inhibitors (TKIs) have limited treatment options. Olverembatinib, which is...
8.
Goulart H, Kantarjian H, Pemmaraju N, Daver N, DiNardo C, Rausch C, et al.
Blood Cancer Discov
. 2024 Nov;
6(1):23-37.
PMID: 39565177
In recent years, there has been tremendous interest surrounding the integration of venetoclax into both non-intensive and intensive chemotherapy regimens for AML. However, with this increasing utilization of venetoclax, considerable...
9.
Kontoyiannis P, Peddireddy A, Sasaki K, Chien K, Senapati J, Montalban-Bravo G, et al.
Leuk Res
. 2024 Nov;
147:107612.
PMID: 39536685
No abstract available.
10.
Short N, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa G, et al.
Lancet Haematol
. 2024 Sep;
11(11):e839-e849.
PMID: 39303729
Background: Advanced phase Philadelphia chromosome-positive myeloid disease-consisting of chronic myeloid leukaemia in the myeloid blast phase and in the accelerated phase, and Philadelphia chromosome-positive acute myeloid leukaemia-is associated with poor...